LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

May 12, 2017: By Joan McKenna

LensarLENSAR, Inc., announced May 11 that it has completed its financial restructuring, with a court-approved exit plan from bankruptcy. As part of the plan, PDL BioPharma will convert most of its debt to an equity ownership position. LENSAR will become a wholly owned subsidiary of PDL, and PDL will begin to consolidate LENSAR’s financial statements.

LENSAR is one of five companies marketing femtosecond lasers for cataract surgery. The Orlando, Florida, company declared bankruptcy in December 2016 in a strategic restructuring designed to separate the business from Alphaeon—Alphaeon acquired LENSAR in late 2015 for a reported $59 million.

On May 5, LENSAR announced it had gained US FDA 510(k) clearance for integration of the Oculus Pentacam and Topcon Aladdin topographers with the LENSAR Laser System with Streamline III.

The LENSAR laser already provided direct integration with the Cassini Corneal Shape Analyzer and the Nidek ODP.

LENSAR describes its next-generation system as designed to help surgeons “manage astigmatism with extreme treatment planning insights.” The company said its incorporation of the diagnostic technology expands the potential customer base.

“Our open architecture platform allows surgeons to use the diagnostic devices they trust to guide treatment and manage astigmatism using our laser’s exclusive features to ultimately deliver the outcomes and experience today’s patients demand from an advanced cataract procedure,” said Nicholas Curtis, CEO of LENSAR.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022